NASDAQ:CALT

Calliditas Therapeutics AB (publ) Stock Forecast, Price & News

$26.88

-0.31 (-1.14 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$26.80

Now: $26.88▼

$27.25

50-Day Range

$26.72

MA: $28.38▼

$30.03

52-Week Range

$19.00

Now: $26.88▼

$38.00

Volume14,993 shs

Average Volume32,682 shs

Market Capitalization$671.22 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CALT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.calliditas.se

Phone46-8411-3005

Employees34

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio23.46

Quick Ratio23.46

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$19.56 million

Price / Sales34.32

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($0.19)

Net Income$-3,450,000.00

Net MarginsN/A

Return on Equity-26.80%

Return on Assets-25.38%

Miscellaneous

Outstanding Shares24,971,000

Market Cap$671.22 million

Next Earnings Date5/13/2021 (Estimated)

OptionableNot Optionable

Headlines

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Given Average Rating of "Buy" by Analysts
April 17, 2021 | americanbankingnews.com

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading Volume
April 12, 2021 | americanbankingnews.com

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading Volume
April 5, 2021 | americanbankingnews.com

Short Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Expands By 211.7%
March 28, 2021 | americanbankingnews.com

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $29.61
March 24, 2021 | americanbankingnews.com

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives Consensus Rating of "Buy" from Analysts
March 23, 2021 | americanbankingnews.com

Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease
March 15, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.39 out of 5 stars

Medical Sector

681st out of 2,025 stocks

Pharmaceutical Preparations Industry

327th out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
Calliditas Therapeutics AB (publ) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.80, Calliditas Therapeutics AB (publ) has a forecasted upside of 51.8% from its current price of $26.88.
Amount of Analyst Coverage
Calliditas Therapeutics AB (publ) has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Calliditas Therapeutics AB (publ) has received 11 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Calliditas Therapeutics AB (publ) has received 9 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Calliditas Therapeutics AB (publ) has received 55.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Calliditas Therapeutics AB (publ) and other stocks. Vote “Outperform” if you believe CALT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CALT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Calliditas Therapeutics AB (publ) does not currently pay a dividend.
Dividend Growth
Calliditas Therapeutics AB (publ) does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Calliditas Therapeutics AB (publ) insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 11.85% of the stock of Calliditas Therapeutics AB (publ) is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Calliditas Therapeutics AB (publ) are expected to grow in the coming year, from ($1.81) to ($1.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Calliditas Therapeutics AB (publ) is -19.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Calliditas Therapeutics AB (publ) is -19.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

$26.88

-0.31 (-1.14 %)

(As of 04/16/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CALT News and Ratings via Email

Sign-up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Frequently Asked Questions

Is Calliditas Therapeutics AB (publ) a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Calliditas Therapeutics AB (publ) stock.
View analyst ratings for Calliditas Therapeutics AB (publ) or view top-rated stocks.

What stocks does MarketBeat like better than Calliditas Therapeutics AB (publ)?

Wall Street analysts have given Calliditas Therapeutics AB (publ) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Calliditas Therapeutics AB (publ) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 24,000 shares, an increase of 211.7% from the February 28th total of 7,700 shares. Based on an average trading volume of 24,600 shares, the short-interest ratio is currently 1.0 days. Currently, 0.1% of the shares of the company are sold short.
View Calliditas Therapeutics AB (publ)'s Short Interest.

When is Calliditas Therapeutics AB (publ)'s next earnings date?

Calliditas Therapeutics AB (publ) is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Calliditas Therapeutics AB (publ).

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings data on Wednesday, February, 17th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.34. The company had revenue of $0.05 million for the quarter.
View Calliditas Therapeutics AB (publ)'s earnings history.

What price target have analysts set for CALT?

5 brokerages have issued 1 year price objectives for Calliditas Therapeutics AB (publ)'s stock. Their forecasts range from $28.00 to $52.00. On average, they anticipate Calliditas Therapeutics AB (publ)'s share price to reach $40.80 in the next twelve months. This suggests a possible upside of 51.8% from the stock's current price.
View analysts' price targets for Calliditas Therapeutics AB (publ) or view top-rated stocks among Wall Street analysts.

Who are Calliditas Therapeutics AB (publ)'s key executives?

Calliditas Therapeutics AB (publ)'s management team includes the following people:

Ms. Renee Aguiar-Lucander, Chief Exec. Officer (Age 59)
Mr. Fredrik Johansson, Chief Financial Officer (Age 44)
Dr. Katayoun Welin-Berger Ph.D., VP of Operations (Age 53)
Dr. Johan Haggblad, Chief Scientific Officer (Age 63)
Mr. Mikael Widell, Head of Communications & IR (Age 63)
Mr. Jonathan A. Schur, Group Gen. Counsel
Ms. Ann-Kristin Myde, Head of Clinical Devel. & VP of Project Management (Age 66)
Mr. Andrew B. Udell B.Sc., M.B.A., Head of North America - Commercial (Age 51)
Dr. Krassimir Mitchev, Head of Medical Affairs (Age 62)
Dr. Richard S. Philipson M.D., Chief Medical Officer (Age 56)

Who are some of Calliditas Therapeutics AB (publ)'s key competitors?

Some companies that are related to Calliditas Therapeutics AB (publ) include Rocket Pharmaceuticals (RCKT), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Intra-Cellular Therapies (ITCI), Ligand Pharmaceuticals (LGND), Xencor (XNCR), ALX Oncology (ALXO), Cryoport (CYRX), Arcus Biosciences (RCUS), Prestige Consumer Healthcare (PBH), Dicerna Pharmaceuticals (DRNA), Zentalis Pharmaceuticals (ZNTL), CytoDyn (CYDY) and NGM Biopharmaceuticals (NGM).
View all of CALT's competitors.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), (EQX) and Forte Biosciences (FBRX).

When did Calliditas Therapeutics AB (publ) IPO?

(CALT) raised $179 million in an IPO on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

What is Calliditas Therapeutics AB (publ)'s stock symbol?

Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT."

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calliditas Therapeutics AB (publ)'s stock price today?

One share of CALT stock can currently be purchased for approximately $26.88.

How much money does Calliditas Therapeutics AB (publ) make?

Calliditas Therapeutics AB (publ) has a market capitalization of $671.22 million and generates $19.56 million in revenue each year. The company earns $-3,450,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

How many employees does Calliditas Therapeutics AB (publ) have?

Calliditas Therapeutics AB (publ) employs 34 workers across the globe.

What is Calliditas Therapeutics AB (publ)'s official website?

The official website for Calliditas Therapeutics AB (publ) is www.calliditas.se.

Where are Calliditas Therapeutics AB (publ)'s headquarters?

Calliditas Therapeutics AB (publ) is headquartered at KUNGSBRON 1 C8, STOCKHOLM V7, 11122.

How can I contact Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The company can be reached via phone at 46-8411-3005 or via email at [email protected]

This page was last updated on 4/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here